Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Sanabani, Sabri Saeed ^a   Nukui, Youko ^a   Pereira, Juliana ^a   da Costa, Antonio Charlys ^a   de Oliveira, Ana Carolina Soares ^a   Pessôa, Rodrigo ^a   Leal, Fabio Eudes ^a   Segurado, Aluisio C ^a   Kallas, Esper Georges ^a   Sabino, Ester Cerdeira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

HAM TSP; HTLV 1; ILB 28 polymorphisms; Proviral load

Indexed keywords

INTERLEUKIN 28B; VIRUS RNA;

ADULT; AGED; ALLELE; ARTICLE; BRAZIL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IL28B GENE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL CORD DISEASE; T CELL LEUKEMIA; T CELL LYMPHOMA; TROPICAL SPASTIC PARAPARESIS; VIRUS GENE; VIRUS LOAD;

ADULT; AGED; FEMALE; GENOTYPE; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; VIRAL LOAD; YOUNG ADULT;

EID: 84872566566     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-374     Document Type: Article

References (40)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980, 77(12):7415-7419. 10.1073/pnas.77.12.7415, 350514, 6261256.
2. Edlich RF, Arnette JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 2000, 18(1):109-119. 10.1016/S0736-4679(99)00173-0, 10645850.
3. Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003, 22(33):5131-5140. 10.1038/sj.onc.1206551, 12910250.
4. Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007, 7(4):266-281. 10.1016/S1473-3099(07)70081-6, 17376384.
5. Franchini G, Ambinder RF, Barry M. Viral Disease in Hematology. Hematology (Am Soc Hematol Educ Program) 2000, 409-423.
6. Murphy EL, Hanchard B, Figueroa JP, Gibbs WN, Lofters WS, Campbell M, Goedert JJ, Blattner WA. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989, 43(2):250-253. 10.1002/ijc.2910430214, 2917802.
7. Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol 2002, 76(Suppl 2):240-245.
8. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007, 7(4):270-280. 10.1038/nrc2111, 17384582.
9. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 1984, 81(8):2534-2537. 10.1073/pnas.81.8.2534, 345097, 6326131.
10. Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, Tanaka Y, Matsuoka M. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer 2004, 109(4):559-567. 10.1002/ijc.20007, 14991578.
11. Mesnard JM, Barbeau B, Devaux C. HBZ, a new important player in the mystery of adult T-cell leukemia. Blood 2006, 108(13):3979-3982. 10.1182/blood-2006-03-007732, 16917009.
12. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999, 19(2):157-169. 10.1055/s-2007-1007107, 10422198.
13. Tsukasaki K, Miller CW, Kubota T, Takeuchi S, Fujimoto T, Ikeda S, Tomonaga M, Koeffler HP. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res 2001, 61(9):3770-3774.
14. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, Bunce M, Ogg GS, Welsh KI, Weber JN, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A 1999, 96(7):3848-3853. 10.1073/pnas.96.7.3848, 22383, 10097126.
15. Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD, Izumo S, Usuku K, Welsh KI, Osame M, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000, 165(12):7278-7284.
16. Nishimura Y, Okubo R, Minato S, Itoyama Y, Goto I, Mori M, Hirayama K, Sasazuki T. A possible association between HLA and HTLV-I-associated myelopathy (HAM) in Japanese. Tissue Antigens 1991, 37(5):230-231. 10.1111/j.1399-0039.1991.tb01877.x, 1771631.
17. Nishimura M, Maeda M, Matsuoka M, Mine H, Saji H, Matsui M, Kuroda Y, Kawakami H, Uchiyama T. Tumor necrosis factor, tumor necrosis factor receptors type 1 and 2, lymphotoxin-alpha, and HLA-DRB1 gene polymorphisms in human T-cell lymphotropic virus type I associated myelopathy. Hum Immunol 2000, 61(12):1262-1269. 10.1016/S0198-8859(00)00182-8, 11163081.
18. Nishimura M, Matsuoka M, Maeda M, Mizuta I, Mita S, Uchino M, Matsui M, Kuroda Y, Kawakami H, Kaji R, et al. Association between interleukin-6 gene polymorphism and human T-cell leukemia virus type I associated myelopathy. Hum Immunol 2002, 63(8):696-700. 10.1016/S0198-8859(02)00419-6, 12121679.
19. Sabouri AH, Saito M, Lloyd AL, Vine AM, Witkover AW, Furukawa Y, Izumo S, Arimura K, Marshall SE, Usuku K, et al. Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2004, 190(7):1279-1285. 10.1086/423942, 15346339.
20. Gadelha SR, Junior Alcantara LC, Costa GC, Acosta AX, Rios D, Kashima S, Covas DT, Galvao-Castro B. Correlation between polymorphisms at interleukin-6 but not at interleukin-10 promoter and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Brazilian individuals. J Med Virol 2008, 80(12)):2141-2146.
21. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399-401. 10.1038/nature08309, 19684573.
22. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41(10):1100-1104. 10.1038/ng.447, 19749758.
23. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41(10):1105-1109. 10.1038/ng.449, 19749757.
24. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139(1):120-129. e118, 10.1053/j.gastro.2010.04.013, 20399780.
25. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138(4):1338-1345. 1345 e1331-1337, 10.1053/j.gastro.2009.12.056, 20060832.
26. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchison J, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24(8):F23-F29. 10.1097/QAD.0b013e3283391d6d, 20389235.
27. Nattermann J, Vogel M, Nischalke HD, Danta M, Mauss S, Stellbrink HJ, Baumgarten A, Mayr C, Bruno R, Tural C, et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis 2011, 203(5):595-601. 10.1093/infdis/jiq098, 3072731, 21257738.
28. Trevino A, Lopez M, Vispo E, Aguilera A, Ramos JM, Benito R, Roc L, Eiros JM, de Mendoza C, Soriano V. Development of Tropical Spastic Paraparesis in Human T-Lymphotropic Virus Type 1 Carriers Is Influenced by Interleukin 28B Gene Polymorphisms. Clin Infect Dis 2012, 55(1):e1-e4. 10.1093/cid/cis343, 22460962.
29. Osame Review of WHO Kagoshima Meeting and diagnostic guidelines for HAM/TSP. Human Retrovirology: HTLV 1990, 191-197. New York: Raven, Blattner W, Osame.
30. Neto WK, Da-Costa AC, de Oliveira AC, Martinez VP, Nukui Y, Sabino EC, Sanabani SS. Correlation between LTR point mutations and proviral load levels among human T cell lymphotropic virus type 1 (HTLV-1) asymptomatic carriers. Virol J 2011, 8:535. 10.1186/1743-422X-8-535, 3287369, 22166003.
31. Scagnolari C, Midulla F, Riva E, Monteleone K, Solimini A, Bonci E, Cangiano G, Papoff P, Moretti C, Pierangeli A, et al. Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis. Virus Res 2012, 165(2):236-240. 10.1016/j.virusres.2012.02.018, 22374338.
32. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR, Izumo S, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998, 4(6):586-593. 10.3109/13550289809114225, 10065900.
33. Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, Ogata M, Kikuchi H, Sagara Y, Uozumi K, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010, 116(8):1211-1219. 10.1182/blood-2009-12-257410, 20448111.
34. Gabet AS, Mortreux F, Talarmin A, Plumelle Y, Leclercq I, Leroy A, Gessain A, Clity E, Joubert M, Wattel E. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 2000, 19(43):4954-4960. 10.1038/sj.onc.1203870, 11042682.
35. Kamihira S, Dateki N, Sugahara K, Hayashi T, Harasawa H, Minami S, Hirakata Y, Yamada Y. Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. Clin Lab Haematol 2003, 25(2):111-117. 10.1046/j.1365-2257.2003.00503.x, 12641615.
36. Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharfe G, Cranston B, Maloney E, Welles SL, Blattner WA, et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 1999, 180(5):1487-1493. 10.1086/315088, 10515807.
37. Jonsson JR, Purdie DM, Clouston AD, Powell EE. Recognition of genetic factors influencing the progression of hepatitis C: potential for personalized therapy. Mol Diagn Ther 2008, 12(4):209-218.
38. Rallon NI, Restrepo C, Naggie S, Lopez M, Del Romero J, Goldstein D, McHutchison J, Soriano V, Benito JM. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS 2011, 25(2):269-271. 10.1097/QAD.0b013e328341b84e, 21099665.
39. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, Buchbinder S, Carrington M, Thio CL. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010, 202(11):1749-1753. 10.1086/657146, 2974014,2974014, 20977343.
40. Kamihira S, Usui T, Ichikawa T, Uno N, Morinaga Y, Mori S, Nagai K, Sasaki D, Hasegawa H, Yanagihara K, et al. Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus. Virol J 2012, 9:40. 10.1186/1743-422X-9-40, 3308917, 22336134.